Novartis and Apellis are competing to get their treatments approved for a rare kidney disease. They have both released new data related to their drugs as part of this race.
Novartis and Apellis Pharmaceuticals are competing to develop treatments for a rare kidney disease. Both companies recently shared promising results […]